L-3,4-methylenedioxyphenylalanine | 32161-31-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-3,4-methylenedioxyphenylalanine
• 英文别名: (2S)-2-azaniumyl-3-(1,3-benzodioxol-5-yl)propanoate
• CAS: 32161-31-2
• 化学式: C₁₀H₁₁NO₄
• 分子量: 209.202
• InChiKey: XHBLRJRZRFZSGW-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  81.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  L-3,4-methylenedioxyphenylalanine 在 lithium aluminium tetrahydride 、 sodium methylate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 9.0h， 生成 (+)-(R)-4-(3,4-methylenedioxybenzyl)-1,3-oxazolidin-2-one
  参考文献：
  名称：

  Design, synthesis, and antitumor activity-absolute configuration relationships of podophyllotoxin aza-analogues

  摘要：

  Optically active and racemic podophyllotoxin aza-analogues 3 approximately 7 were designed and synthesized by a highly stereoselective condensation reaction of a cyclic urethane 10 or 16 with 3,4,5-trimethoxybenzaldehyde 11 and were found to show a promising in vitro and in vivo antitumor activity.

  DOI：

  10.1016/s0040-4020(01)80545-7
• 作为产物：
  描述：

  (2R,3S)-2,3-dihydroxy-3-(3,4-methylenedioxyphenyl)propionate 在 氯化亚砜 、 三乙胺 作用下， 反应 0.75h， 生成 L-3,4-methylenedioxyphenylalanine
  参考文献：
  名称：

  Asymmetric synthesis of l-DOPA and (R)-selegiline via, OsO4-catalyzed asymmetric dihydroxylation

  摘要：

  A simple and effective procedure for the enantioselective synthesis of two important neurotransmitter drugs, hat is, (S)-3,4-dihydroxyphenylalanine (L-DOPA) and (R)-N,alpha-dimethyl-N-2-propynylbenzeneethaneamine [(R)-selegiline], is described by employing the Sharpless asymmetric dihydroxylation (AD) as a key step to introduce chirality. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2004.08.007

文献信息

• 1,5-Dimethyl-4-phenylimidazolidin-2-one-Derived Iminic Glycinimides:  Useful New Reagents for Practical Asymmetric Synthesis of α-Amino Acids
  作者：Gabriela Guillena、Carmen Nájera

  DOI：10.1021/jo000321t

  日期：2000.11.1

  two-step procedures with LiOOH or LiOH followed by acidic hydrolysis or Dowex purification, (b) in one single-step under refluxing water to give the corresponding alpha-amino acid, (c) in the presence of DBU in methanol to provide N-protected alpha-amino acids methyl esters, or (d) by a protection-hydrolysis procedure to afford N-Boc-protected alpha-amino acids. The chiral imidazolidinone has generally been

  已制备了新的1,5-二甲基-4-苯基咪唑啉二-2-酮衍生的无环手性亚胺基甘氨酸试剂，并在（a）强碱（LHMDS，KOBu）下，在氯化锂存在下，用活化的烷基卤化物和亲电烯烃非对映选择性烷基化。 （t））和低温（-78摄氏度）条件，（b）固液相转移催化反应（LiOH，TBAB，-20摄氏度）条件和（c）在有机碱（DBU）存在下，BEMP，TMG，-20摄氏度）。在双亲电子试剂的情况下，发生C-和N-烷基化以提供杂环衍生物。（a）用LiOOH或LiOH分两步进行水解，然后进行酸性水解或Dowex纯化，（b）在回流水中一步一步得到相应的α-氨基酸，进行了烷基化产物的水解。（c）在甲醇中的DBU存在下提供N-保护的α-氨基酸甲酯，或（d）通过保护-水解程序得到N-Boc保护的α-氨基酸。通常已以良好的收率回收了手性咪唑啉酮。已经证明该方法对于合成无环和杂环的（S）-和（R）-α-氨基酸是有用的。
• Discovery of Biased Mu‐Opioid Receptor Agonists for the Treatment of Pain
  作者：Mengjun Ma、Xiang Li、Kun Tong、Jingchao Cheng、Zixing Yu、Fengxia Ren、Bohua Zhong、Weiguo Shi

  DOI：10.1002/cmdc.201900575

  日期：2020.1.7

  agonists have been developed as promising new potent analgesic drugs with fewer adverse side effects than standard MOR agonists. PZM21 represents a unique chemotype unrelated to known opioids, which makes it a desirable lead for modification to find analgesics with new chemical entities. In the present study, we synthesized and tested novel PZM21 derivatives as potent biased MOR agonists by introducing a benzodioxolane

  G蛋白偏向型阿片受体（MOR）激动剂已被开发为有前景的新型有效止痛药，与标准MOR激动剂相比，副作用更少。PZM21代表与已知阿片类药物无关的独特化学型，这使其成为进行修饰以寻找具有新化学实体的止痛药的理想先导。在本研究中，我们通过引入苯并二氧戊环基团取代PZM21的羟基苯，合成并测试了新型PZM21衍生物作为强效的MOR激动剂。与PZM21相比，新化合物在体内显示出更强的镇痛活性，并在体外对G蛋白信号传导产生更大的偏见。这些结果表明，苯并二氧戊环基团对于维持偏倚是必不可少的。化合物7 i（（S）-1-（3-（苯并[d] [1，
• 6-[.alpha.-AMINO-.omega.-(3,4-METHYLENEDIOXYPHENYL)ACYLAMIDO]PEN
  申请人：Richardson-Merrell Inc.

  公开号：US03994877A1

  公开（公告）日：1976-11-30

  Novel 6-[.alpha.-amino-.omega.-(3,4-methylenedioxyphenyl)acylamido] penicillanic acid derivatives are prepared which are useful as antibacterial agents.

  制备了一种6-[.alpha.-氨基-.omega.-(3,4-二甲氧基苯基)酰胺基]青霉烷酸衍生物，可用作抗菌剂。
• 7-[.alpha.-Amino-
  申请人：Richardson-Merrell Inc.

  公开号：US04020060A1

  公开（公告）日：1977-04-26

  Novel 7-[.alpha.-amino-.omega.-(3,4-methylenedioxyphenyl)acylamido]cephalosporan ic acid derivatives are prepared which are useful as antibacterial agents.

  制备了新型的7-[α-氨基-ω-(3,4-亚甲二氧基苯基)酰胺基]头孢菌素衍生物，可用作抗菌剂。
• 2-Aminooxazolines as TAAR1 ligands
  申请人：Galley Guido

  公开号：US20080261920A1

  公开（公告）日：2008-10-23

  The invention relates to compounds of formula I wherein X, Y, R 1 , R 2 , and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及化合物I的公式，其中X，Y，R1，R2和n如本文所定义，或其药学上适宜的酸加盐。本发明还涉及含有这种化合物的制药组合物和治疗与微量胺相关受体的生物学功能相关的疾病的方法，这些疾病包括抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神障碍、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢性疾病、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管疾病。